2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 777

a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus
Abstract Number: 778

WITHDRAWN
Abstract Number: 779

Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 780

Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Abstract Number: 781

The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Abstract Number: 782

Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
Abstract Number: 783

Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
Abstract Number: 784

Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
Abstract Number: 785

What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis
Abstract Number: 786

Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Abstract Number: 787

Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Abstract Number: 788

Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
Abstract Number: 789

Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
Abstract Number: 790

Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Abstract Number: 791

The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].